ForPatients
by Roche

Alzheimer's Disease (AD)

A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease

Trial Status	Trial Runs In	Trial Identifier
Completed	24 Countries	NCT01224106 2010-019895-66 WN25203

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This multi-center, randomized, double-blind, placebo-controlled parallel-group study will evaluate the effect of gantenerumab (RO4909832) on cognition and functioning and the safety and pharmacokinetics in participants with prodromal Alzheimer's Disease. Participants will be randomized to receive subcutaneous (SC) injections of either gantenerumab or placebo. Participants who consent to be part of the sub study will undergo positron emission tomography (PET) scanning to assess brain amyloid. The anticipated time on study treatment is 104 weeks in Part 1, with an option for an additional up to 2 years of treatment in Part 2, followed by an open-label extension (Part 3) until July 2020. The dosing for Parts 1 and 2 was stopped after a planned futility interim analysis showed a low probability of meeting the primary outcome measure with the doses studied. The study has converted to open-label to investigate higher gantenerumab doses.

Hoffmann-La Roche Sponsor	**Phase 3** Phase

NCT01224106 2010-019895-66 WN25203
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=50 Years & <= 85 Years	No